Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.

W. K. O'Neal, H. Zhou, Nuria Morral, C. Langston, R. J. Parks, F. L. Graham, S. Kochanek, A. L. Beaudet

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

BACKGROUND: Certain gene therapy protocols may require multiple administrations of vectors to achieve therapeutic benefit to the patient. This may be especially relevant for vectors such as adenoviral vectors that do not integrate into the host chromosome. Because immunocompetent animal models used for gene transfer studies develop neutralizing antibodies to adenoviral vectors after a single administration, little is known about how repeat administrations of vectors might affect transgene expression and vector toxicity. MATERIALS AND METHODS: We used mice deficient in the membrane spanning region of immunoglobulin (IgM), which do not develop antibodies, to evaluate the effect of repeated intravenous administration of first-generation and helper-dependent adenoviral vectors expressing human alpha 1-antitrypsin (hAAT). The duration and levels of transgene expression were evaluated after repeated administration of vectors. Toxicity was assessed by measuring the level of liver enzymes in the serum and the degrees of hepatocyte hypertrophy and proliferation. RESULTS: We found that previous administration of first-generation adenoviral vectors can alter the response to subsequent doses. These alterations included an increase in transgene expression early (within 1 and 3 days), followed by a rapid drop in expression by day 7. In addition, previous administrations of first-generation vectors led to an increase in toxicity of subsequent doses, as indicated by a rise in liver enzymes and an increase in hepatocyte proliferation. In contrast to first-generation vectors, use of the helper-dependent adenovirus vector, Ad-STK109, which contained no viral coding regions, did not lead to increased toxicity after multiple administrations. CONCLUSIONS: We conclude that the response of the host to adenoviral vectors can be altered after repeated administration, compared with the response after the initial vector dose. In addition, these experiments provide further evidence for the relative safety of helper-dependent adenoviral vectors for gene therapy, compared with first-generation vectors.

Original languageEnglish (US)
Pages (from-to)179-195
Number of pages17
JournalMolecular Medicine
Volume6
Issue number3
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

Transgenes
Adenoviridae
Genetic Therapy
Hepatocytes
alpha 1-Antitrypsin
Liver
Enzymes
Neutralizing Antibodies
Intravenous Administration
Hypertrophy
Immunoglobulin M
Immunoglobulins
Animal Models
Chromosomes
Safety
Membranes
Antibodies
Serum
Genes
Therapeutics

ASJC Scopus subject areas

  • Genetics

Cite this

O'Neal, W. K., Zhou, H., Morral, N., Langston, C., Parks, R. J., Graham, F. L., ... Beaudet, A. L. (2000). Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Molecular Medicine, 6(3), 179-195.

Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. / O'Neal, W. K.; Zhou, H.; Morral, Nuria; Langston, C.; Parks, R. J.; Graham, F. L.; Kochanek, S.; Beaudet, A. L.

In: Molecular Medicine, Vol. 6, No. 3, 03.2000, p. 179-195.

Research output: Contribution to journalArticle

O'Neal, WK, Zhou, H, Morral, N, Langston, C, Parks, RJ, Graham, FL, Kochanek, S & Beaudet, AL 2000, 'Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.', Molecular Medicine, vol. 6, no. 3, pp. 179-195.
O'Neal, W. K. ; Zhou, H. ; Morral, Nuria ; Langston, C. ; Parks, R. J. ; Graham, F. L. ; Kochanek, S. ; Beaudet, A. L. / Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. In: Molecular Medicine. 2000 ; Vol. 6, No. 3. pp. 179-195.
@article{153caa4c8b0b4f62a0c3579e248fe6f8,
title = "Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.",
abstract = "BACKGROUND: Certain gene therapy protocols may require multiple administrations of vectors to achieve therapeutic benefit to the patient. This may be especially relevant for vectors such as adenoviral vectors that do not integrate into the host chromosome. Because immunocompetent animal models used for gene transfer studies develop neutralizing antibodies to adenoviral vectors after a single administration, little is known about how repeat administrations of vectors might affect transgene expression and vector toxicity. MATERIALS AND METHODS: We used mice deficient in the membrane spanning region of immunoglobulin (IgM), which do not develop antibodies, to evaluate the effect of repeated intravenous administration of first-generation and helper-dependent adenoviral vectors expressing human alpha 1-antitrypsin (hAAT). The duration and levels of transgene expression were evaluated after repeated administration of vectors. Toxicity was assessed by measuring the level of liver enzymes in the serum and the degrees of hepatocyte hypertrophy and proliferation. RESULTS: We found that previous administration of first-generation adenoviral vectors can alter the response to subsequent doses. These alterations included an increase in transgene expression early (within 1 and 3 days), followed by a rapid drop in expression by day 7. In addition, previous administrations of first-generation vectors led to an increase in toxicity of subsequent doses, as indicated by a rise in liver enzymes and an increase in hepatocyte proliferation. In contrast to first-generation vectors, use of the helper-dependent adenovirus vector, Ad-STK109, which contained no viral coding regions, did not lead to increased toxicity after multiple administrations. CONCLUSIONS: We conclude that the response of the host to adenoviral vectors can be altered after repeated administration, compared with the response after the initial vector dose. In addition, these experiments provide further evidence for the relative safety of helper-dependent adenoviral vectors for gene therapy, compared with first-generation vectors.",
author = "O'Neal, {W. K.} and H. Zhou and Nuria Morral and C. Langston and Parks, {R. J.} and Graham, {F. L.} and S. Kochanek and Beaudet, {A. L.}",
year = "2000",
month = "3",
language = "English (US)",
volume = "6",
pages = "179--195",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "3",

}

TY - JOUR

T1 - Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.

AU - O'Neal, W. K.

AU - Zhou, H.

AU - Morral, Nuria

AU - Langston, C.

AU - Parks, R. J.

AU - Graham, F. L.

AU - Kochanek, S.

AU - Beaudet, A. L.

PY - 2000/3

Y1 - 2000/3

N2 - BACKGROUND: Certain gene therapy protocols may require multiple administrations of vectors to achieve therapeutic benefit to the patient. This may be especially relevant for vectors such as adenoviral vectors that do not integrate into the host chromosome. Because immunocompetent animal models used for gene transfer studies develop neutralizing antibodies to adenoviral vectors after a single administration, little is known about how repeat administrations of vectors might affect transgene expression and vector toxicity. MATERIALS AND METHODS: We used mice deficient in the membrane spanning region of immunoglobulin (IgM), which do not develop antibodies, to evaluate the effect of repeated intravenous administration of first-generation and helper-dependent adenoviral vectors expressing human alpha 1-antitrypsin (hAAT). The duration and levels of transgene expression were evaluated after repeated administration of vectors. Toxicity was assessed by measuring the level of liver enzymes in the serum and the degrees of hepatocyte hypertrophy and proliferation. RESULTS: We found that previous administration of first-generation adenoviral vectors can alter the response to subsequent doses. These alterations included an increase in transgene expression early (within 1 and 3 days), followed by a rapid drop in expression by day 7. In addition, previous administrations of first-generation vectors led to an increase in toxicity of subsequent doses, as indicated by a rise in liver enzymes and an increase in hepatocyte proliferation. In contrast to first-generation vectors, use of the helper-dependent adenovirus vector, Ad-STK109, which contained no viral coding regions, did not lead to increased toxicity after multiple administrations. CONCLUSIONS: We conclude that the response of the host to adenoviral vectors can be altered after repeated administration, compared with the response after the initial vector dose. In addition, these experiments provide further evidence for the relative safety of helper-dependent adenoviral vectors for gene therapy, compared with first-generation vectors.

AB - BACKGROUND: Certain gene therapy protocols may require multiple administrations of vectors to achieve therapeutic benefit to the patient. This may be especially relevant for vectors such as adenoviral vectors that do not integrate into the host chromosome. Because immunocompetent animal models used for gene transfer studies develop neutralizing antibodies to adenoviral vectors after a single administration, little is known about how repeat administrations of vectors might affect transgene expression and vector toxicity. MATERIALS AND METHODS: We used mice deficient in the membrane spanning region of immunoglobulin (IgM), which do not develop antibodies, to evaluate the effect of repeated intravenous administration of first-generation and helper-dependent adenoviral vectors expressing human alpha 1-antitrypsin (hAAT). The duration and levels of transgene expression were evaluated after repeated administration of vectors. Toxicity was assessed by measuring the level of liver enzymes in the serum and the degrees of hepatocyte hypertrophy and proliferation. RESULTS: We found that previous administration of first-generation adenoviral vectors can alter the response to subsequent doses. These alterations included an increase in transgene expression early (within 1 and 3 days), followed by a rapid drop in expression by day 7. In addition, previous administrations of first-generation vectors led to an increase in toxicity of subsequent doses, as indicated by a rise in liver enzymes and an increase in hepatocyte proliferation. In contrast to first-generation vectors, use of the helper-dependent adenovirus vector, Ad-STK109, which contained no viral coding regions, did not lead to increased toxicity after multiple administrations. CONCLUSIONS: We conclude that the response of the host to adenoviral vectors can be altered after repeated administration, compared with the response after the initial vector dose. In addition, these experiments provide further evidence for the relative safety of helper-dependent adenoviral vectors for gene therapy, compared with first-generation vectors.

UR - http://www.scopus.com/inward/record.url?scp=0034152718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034152718&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 179

EP - 195

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 3

ER -